Sutherland Unveils Insurance AI Hub to Break Industry’s ‘Pilot Trap’
13.10.2025 14:41:00 CEST | Business Wire | Press Release
Sutherland, a global leader in business and digital transformation, today announced the launch of its Insurance AI Hub, an agentic AI ecosystem engineered to solve the scale, compliance, and ROI challenges insurers face in operationalizing AI.
Unlike generalized AI platforms retrofitted for insurance or siloed tools that rarely make it beyond the demo stage, Sutherland’s solution is trained on real insurance workflows, tuned for regulatory demands, and already being deployed by enterprises today.
Now with a comprehensive suite of specialized AI agents engineered for Life & Annuity, Group Benefits, Property & Casualty, and Specialty lines, the Insurance AI Hub lets insurers break free from proof-of-concept paralysis and finally scale AI with confidence.
Sutherland’s AI offerings come with important enterprise guardrails already in place, featuring a human-in-the-loop framework, audit trails, and model transparency built in. It provides a true “ecosystem” purpose-built for insurance—from the infrastructure and models selected to the tailored use cases.
The Insurance AI Hub is already delivering impact across the policy lifecycle:
- Agentic AI for Claims & Enrollment streamlines complex disability and life claims with human-in-the-loop precision—cutting cycle times by up to 30%, reducing leakage by 12%, and lifting claimant satisfaction by 10+%.
- Voice AI engages customers through natural, human-like conversations across claims, servicing, and sales—boosting contact center efficiency by 20%, improving conversion by up to 3%, and increasing NPS by 10+ points.
- Connected Underwriting empowers underwriters with AI-driven triage and appetite matching—delivering 30% efficiency gains, 16% higher win rates, and 3.7x growth in high-appetite business.
- Cognilink Document Intelligence transforms manual, document-heavy workflows into automated, insight-driven processes—cutting OPEX by 30%, improving indemnity by 1–1.5%, and reducing leakage by 10–12%.
“Insurers don’t need more AI pilots—they need outcomes,” said Banwari Agarwal, CEO of Insurance, Banking and Financial Services at Sutherland. “The Insurance AI Hub was built with insurance DNA from day one. It delivers scalable agentic automation that understands the industry’s complexities, integrates into fragmented IT environments, and provides measurable results—not just demos.”
At its core, the Insurance AI Hub uses a modular, plug-and-play architecture that allows each AI agent to operate autonomously or collaboratively across claims, underwriting, servicing, and renewals. This enables insurers to accelerate adoption while maintaining full transparency, bias controls, and compliance alignment with SOC 2, HIPAA, and NAIC regulations.
With most insurers having already contracted with hyperscalers and tested GenAI in narrow pilots, the industry now faces its biggest hurdle: trusting the tools to scale and provide measurable ROI. The Sutherland Insurance AI Hub was built to bridge that gap.
About Sutherland
Artificial Intelligence. Automation. Cloud Engineering. Advanced Analytics.
For Enterprises, these are key factors of success. For us, they’re our core expertise.
We work with global iconic brands. We bring them a unique value proposition through market-leading technologies and business process excellence. At the heart of it all is Digital Engineering – the foundation that powers rapid innovation and scalable business transformation.
We’ve created 363 unique and independent inventions, 250 of which are AI-based and rolled up under several patent grants in critical technologies. Leveraging our advanced products and platforms, we drive digital transformation at scale, optimize critical business operations, reinvent experiences, and pioneer new solutions, all provided through a seamless “as-a-service” model.
For each company, we provide new keys for their businesses, the people they work with, and the customers they serve. With proven strategies and agile execution, we don’t just enable change — we engineer digital outcomes.
Know more: www.sutherlandglobal.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20251013128638/en/
Contacts
For further queries: mediarelations@sutherlandglobal.com
Know more: www.sutherlandglobal.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sutherlandg
lobal.com%2F&esheet=54337278&newsitemid=20251013128638&lan=en-US&anchor=www.suth
erlandglobal.com&index=4&md5=5f999be206af38a6a1dcf144e7e411e6
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom